checkAd
    Startseite > Aktien > Medicenna Therapeutics > Nachrichten
    Medicenna Therapeutics Aktie
    2,8500
     
    CAD
    +22,84 %
    +0,5300 CAD
    Letzter Kurs 31.05.24 Toronto
    2,8000
     
    CAD
    700 STK
    Geldkurs 31.05.24
    2,8500
     
    CAD
    1.000 STK
    Briefkurs 31.05.24
    ISIN: CA58490H1073 · WKN: A2PA4V · SYM: MDNA · Kanada

    Neueste Nachrichten

    Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
    31.05.24 · globenewswire · Medicenna Therapeutics
    Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum
    22.05.24 · globenewswire · Medicenna Therapeutics
    Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
    13.05.24 · globenewswire · Medicenna Therapeutics
    Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
    30.04.24 · globenewswire · Medicenna Therapeutics
    Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
    26.04.24 · globenewswire · Medicenna Therapeutics
    Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
    24.04.24 · globenewswire · Medicenna Therapeutics
    Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
    10.04.24 · globenewswire · Medicenna Therapeutics
    Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
    09.04.24 · globenewswire · Medicenna Therapeutics
    Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
    09.04.24 · globenewswire · Medicenna Therapeutics
    Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
    04.04.24 · globenewswire · Medicenna Therapeutics
    Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
    06.03.24 · globenewswire · Medicenna Therapeutics
    Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
    14.02.24 · globenewswire · Medicenna Therapeutics